Company news
Intensity Therapeutics, Inc. news in 2025
Intensity Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
December 11, 2025
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
December 5, 2025
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
December 4, 2025
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 6, 2025
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
October 31, 2025
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
October 30, 2025
Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
September 10, 2025
Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
August 12, 2025
Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 7, 2025
Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025
August 4, 2025
Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)
June 30, 2025
Intensity Therapeutics, Inc. Announces Pricing of Public Offering
June 11, 2025
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
June 11, 2025
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study
June 11, 2025
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
May 29, 2025
Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon
May 28, 2025
Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France
May 6, 2025
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering
April 25, 2025
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
March 13, 2025
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
January 27, 2025
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
January 9, 2025
Decks in 2025
- IPO Roadshow (June 2025)
IPO roadshow · 28 slides · Jun 11, 2025
- Investor Presentation (April 2025)
Investor deck · 28 slides · Apr 23, 2025
- IPO Roadshow (April 2025)
IPO roadshow · 29 slides · Apr 23, 2025